Bextra and Vioxx Withdrawal Spurs Price Increase Among Rivals
The market for painkillers is huge. People don't like pain and inflammation, and last year Americans spent nearly $4 billion on just two of them - Vioxx and Bextra. Those two drugs, part of a family of non-steroidal anti-inflammatory drugs known as COX-2 inhibitors, were withdrawn from the market recently amid concerns that they can cause heart attacks and strokes. The loss of these two drugs to the marketplace is huge, as they were the two largest sellers in a fairly narrow field. COX-2 inhibitors differ from traditional non-steroidal anti-inflammatory drugs in that they inhibit production of the COX-2 enzyme that causes inflammation but do not interfere with COX-1, the enzyme that protects the stomach lining. Patients who use these drugs are thought to suffer less from internal discomfort and bleeding than those who took traditional anti-inflammatories, such as naproxen and ibuprofen.
With the withdrawal of these two blockbusters, patients with chronic pain, such as arthritis sufferers, are now going back to older painkillers, such as Mobic, Motrin, and Relafen. Since the more popular Vioxx and Bextra are no longer available, these older drugs are enjoying a resurgence in popularity, and sales are up across the board. So, it seems, are their prices. A recent study by a popular consumer publication shows that prices of some three dozen anti-inflammatory medications have gone up since Vioxx was withdrawn from the market in September 2004. The increases average about ten percent. Why have the prices of these older, established medications all gone up at once?
The answer, simply, is that the pharmaceutical companies have raised the prices because they can. The market for drugs is wildly competitive, and manufacturers are constantly seeking any advantage they can find in the marketplace. The sudden withdrawal of two of the most popular and profitable medications has provided a rare opportunity for manufacturers to increase both sales and prices at the same time, as the drug makers know that patients must switch to another medication. It's good for their stockholders, but bad for those who suffer from pain.
Will the high prices last? Probably not. Pricing of highly competitive medications tends to be volatile. The prices may stay up in the short term, but other medications may be introduced soon, or Bextra or Vioxx may be returned to the market. The introduction of other drugs will restore more competition to the market, and prices may drop once again. The market for painkilling drugs is a bit of a crazy one, and patients should simply exhibit some, well, patience.
©Copyright 2005 by Retro Marketing.
Charles Essmeier is the owner of Retro Marketing, a firm devoted to informational Websites, including Bextra-Info.net, a site devoted to the withdrawn drug Bextra and StructuredSettlementHelp.com, a site devoted to structured settlements.
Latest News
BioImagene CEO, Dr. Ajit Singh, Speaks On Enabling Personalized ... MarketWatch - Digital pathology, a key enabler for personalized medicine, will aid clinicians in managing and interpreting data from a whole new set of diagnostic tests ... Aperio Introduces SecondSlide(TM) Digital Slide Sharing Network |
Boston Globe | Medicine for the Job Market New York Times, United States - By JONATHAN GRUBER A CENTRAL feature of Barack Obama’s presidential campaign was an aggressive plan to expand health insurance coverage by subsidizing ... New Report Shows Slower Premium Growth, But Increasing Pressure to ... Health Corps Research database from the US Library of Medicine |
SmartAboutHealth | American College of Surgeons Comments on Institute of Medicine ... MarketWatch - CHICAGO, Dec 03, 2008 /PRNewswire-USNewswire via COMTEX/ -- The American College of Surgeons (ACS) today recognized the Institute of Medicine (IOM) for its ... BMC Internal Medicine Residency Program Achieves National ... Report urges more sleep for medical residents Medical Residents Must Sleep After 16 Hours, Experts Urge |
Research and Markets: 2008 Integrative Medicine and Dietary ... MarketWatch - In this 32-page issue, we offer a breakdown of 2007 US Complementary and Alternative Medicine sales data and provides a detailed analysis of new integrative ... |
![]() Javno.hr | 34 Nigerian Children Dead From Tainted Medicine Voice of America - By VOA News Nigerian health officials say they are flying in doses of an antidote for a poisoned teething medicine that has now killed 34 infants. ... 'Toxic' syrup kills Nigerian babies Teething mixture kills more Nigerian babies Nigeria infant drug toll hits 34, antidote flown in |
Research database from the US Library of Medicine The Plain Dealer - cleveland.com, OH - Search PubMed, Clinicaltrials.gov, the CDC and a dozen other medical sites - all at once. AP MEDICAL VIDEO by Michael O'Malley and Joan Mazzolini/Plain ... |
A New Index of Preventive Medicine Companies Motley Fool - The accompanying table [click to enlarge] presents statistics and the top 15 rated companies in the ETF Innovators [ETFI] Preventive Medicine Index. ... |
American Academy of Dermatology Issues Position Statement on Vitamin D MarketWatch - The currently recommended adequate intake levels established by the Institute of Medicine may be revised upward due to evolving research on the increasing ... |
NIGERIA: Jos displaced grapple with food, water, medicine shortages IRINnews.org, NY - JOS, 4 December 2008 (IRIN) - Water, medicine and food supplies are running low for an estimated 10000 people displaced by violence in Jos, northern Nigeria ... |
![]() Discover Magazine | "Rogue" stem cell clinics exploit hope: report Reuters - "The direct-to-consumer portrayal of stem cell medicine is optimistic and unsupported by published evidence," Timothy Caulfield of the University of Alberta ... Scientists warn of “rogue” online stem cell clinics Internet stem-cell clinics 'exploiting' MS and Parkinson's patients The International Society for Stem Cell Research Releases New ... |
Resources
-
Sorry Currently Unavailable

